Drug-Stocks im Aufwind

kurz billig eingesammelt.  

 

 

gebraucht.  Gewusst wie!  

Kurs wird mit Miniumsatz runtergezogen, um dann abzuräumen.  Gleiches Spiel wie gestern.  

Gekommen.... Kann die wer deuten? Bin mit dem handy den ganzen tag unterwegs und mein englisch is not good :)  

Amended Annual Report (10-k/a)


UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 10-K/A
Amendment No. 1

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the Year Ended September 30, 2012
File Number: 0-32201


BIO-MATRIX SCIENTIFIC GROUP, INC.
(Exact name of registrant as specified in its charter)
 
   
  DELAWARE§   33-0824714
(State of jurisdiction of Incorporation)   (I.R.S. Employer Identification No.)
   
4700 SPRING STREET, SUITE 304, LA MESA, CALIFORNIA,   91942
(Address of principal executive offices)   (Zip Code)

(619) 702-1404
(Registrants telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

 
Title of Each Class
to be so Registered:
Name of each exchange on which registered:
      None§ None

Securities registered under Section 12(g) of the Act:

Common Stock, Par Value $.0001
(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes☐ No ☑

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months, (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☑

 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in the definitive proxy or information statement incorporated by reference in Part III of this Form 10-K or amendment to Form 10-K.☐

Indicate by check mark whether the registrant is a large accelerated filer, and accelerated filer, a non-accelerated filer, or a small reporting company. See definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large Accelerated Filer ☐   Accelerated Filer                  ☐
Non-accelerated Filer    ☐   Smaller reporting company ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐  No ☑

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☐ No ☑

As of March 31, 2012, the aggregate market value of the issued and outstanding common stock held by non-affiliates of the registrant, based upon the closing price of the common stock, under the symbol “BMSN” as quoted on the OTC market of $0.095., was approximately $564,979.  For purposes of the statement in the preceding statement, all directors, executive officers and 10% shareholders are assumed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for any other purpose.

Number of shares outstanding of each of the issuer's class of common stock as of  February 19,2013:
Common: 1,125,911,549
Preferred: 1,963,821.
Series AA Preferred: 94,852
Series B Preferred: 725,409

In this annual report, the terms “Bio-Matrix Scientific Group Inc.”,  “Company”,  “us”, “we”, or “our”, unless the context otherwise requires, mean Bio-Matrix Scientific Group,  Inc., a Delaware corporation, and its subsidiaries.

This annual report on Form 10-K and other reports that we file with the SEC contain statements that are considered forward-looking statements.  Forward-looking statements give the Company’s current expectations, plans, objectives, assumptions or forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding the Company’s future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plans,” “potential,” “projects,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend,” and similar expressions. These statements are based on the Company’s current plans and are subject to risks and uncertainties, and as such the Company’s actual future activities and results of operations may be materially different from those set forth in the forward looking statements. Any or all of the forward-looking statements in this annual report may turn out to be inaccurate and as such, you should not place undue reliance on these forward-looking statements.  The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and assumptions due to a number of factors, including:


 
         *§ dependence on key personnel;
         *§ competitive factors;
         *§ degree of success of research and development programs
         *§ the operation of our business; and
         *§ general economic conditions

These forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.

EXPLANATORY NOTE:
THIS AMENDMENT NO.1 TO BIO-MATRIX SCIENTIFIC GROUP, INC’S (THE “COMPANY”) FORM 10-K FOR THE PERIOD ENDED SEPTEMBER 30, 2012 (“FORM 10-K”) IS BEING FILED SOLELY TO CORRECT A TYPOGRAPHICAL ERROR. THE  CONSOLIDATED STATEMENT OF OPERATIONS FOR THE 12 MONTHS ENDED SEPTEMBER 30, 2011 REPORTED LOSS ON SALE OF AVAILABLE FOR SALE SECURITIES OF $487,900 AND THE  CONSOLIDATED STATEMENT OF OPERATIONS FOR THE PERIOD FROM INCEPTION TO SEPTEMBER 30, 2012 REPORTED LOSS ON SALE OF AVAILABLE FOR SALE SECURITIES OF $0. IN ACTUALITY LOSS ON SALE OF AVAILABLE FOR SALE SECURITIES WAS $0 AND $487,900 FOR THE 12 MONTHS ENDED SEPTEMBER 30, 2011 AND FROM INCEPTION TO SEPTEMBER 30, 2012 RESPECTIVELY
 



Item 8. Financial Statements and Supplementary Data
 
SEALE AND BEERS, CPAs
PCAOB & CPAB REGISTERED AUDITORS

www.sealebeers.com


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors and Stockholders of

Bio-Matrix Scientific Group, Inc.

(A Development Stage Company)

We have audited the accompanying balance sheets of Bio-Matrix Scientific Group, Inc. as of September 30, 2012, and the related statements of income, stockholders’ equity (deficit), and cash flows for the year ended September 30, 2012, and from inception on October 6, 1998 through September 30, 2012. Bio-Matrix Scientific Group, Inc.’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Bio-Matrix Scientific Group, Inc. as of September 30, 2012, and the related statements of income, stockholders’ equity (deficit), and cash flows for year in the ended September 30, 2012, and from inception on October 6, 1998 through September 30, 2012, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 5 to the financial statements, the Company has no revenues, has negative working capital at September 30, 2012, has incurred recurring losses and recurring negative cash flow from operating activities, and has an accumulated deficit which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 5. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.



/s/ Seale and Beers, CPAs

Seale and Beers, CPAs

Las Vegas, Nevada

February 25, 2013



50 S. Jones Blvd. Suite 202 Las Vegas, NV 89107 Phone: (888)727-8251 Fax: (888)782-2351




REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To: The Board of Directors and Stockholders
Bio-Matrix Scientific Group Inc.

I have audited the accompanying consolidated balance sheet of Bio-Matrix Scientific Group Inc. as of September 30, 2011 and 2010 and the related statements of operations, stockholders’ equity and cash flows for the years ended September 30, 2011 and 2010,  and the period from inception (August 2, 2005) to September 30, 2011. These financial statements are the responsibility of the Company’s management.  My responsibility is to express an opinion on these financial statements based on my audit.

I conducted my audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  The Company is not required to have, nor was I engaged to perform, an audit of its internal control over financial reporting.  My audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but do not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.  Accordingly, I express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  I believe that my audit provides a reasonable basis for my opinion.

In my opinion, the financial statements referred to in the first paragraph present fairly, in all material respects, the financial position of Bio-Matrix Scientific Group Inc. as of September 30, 2011 and 2010 and the results of its operations and changes in stockholders’ equity and cash flows for the years ended September 30, 2011 and 2010, and the period from inception (August 2, 2005) to September 30, 2011 in conformity with accounting principles generally accepted in the United States.

The accompanying financial statements have been prepared assuming that the Company is a going concern.  As discussed in Note 5  to the financial statements, the Company has not generated income and has accumulated losses.  This raises substantive doubt about the Company’s ability to continue as a going concern.  Management’s plans in regard to these matters are also described in Note 5.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/ s / John Kinross-Kennedy
John Kinross-Kennedy
Certified Public Accountant
Irvine, California
December 22, 2011



BIOMATRIX SCIENTIFIC GROUP, INC.        
(A Development Stage Company)        
Consolidated Balance Sheet        
  As of   As of
  September 30, 2012   September 30, 2011
    ASSETS§        
CURRENT ASSETS                
      Cash§   $ 75,752     $ 331  
Prepaid Expenses     15,000       39,925  
    Total Current Assets     90,752       40,256  
PROPERTY & EQUIPMENT (Net of Accumulated Depreciation)     0       20,789  
OTHER ASSETS                
  Deposits§     4,200       4,200  
Deferred Financing Costs     65,000       0  
Investment in Subsidiary             41,735,443  
Available for Sale Securities     22,000       0  
Total Other Assets     91,200       41,739,643  
TOTAL ASSETS   $ 181,952     $ 41,800,688  
LIABILITIES AND STOCKHOLDERS' EQUITY                
CURRENT LIABILITIES                
Accounts Payable     133,039       130,507  
Notes Payable     817,020       169,575  
Accrued Payroll     307,692       627,000  
Accrued Payroll Taxes     27,769       23,780  
Accrued Interest     210,069       154,930  
Accrued Expenses     5,000       5,000  
Convertible Note Payable Net of  Unamortized Discount     300,509       313,701  
Due to Affiliate     39,140       59,500  
Current portion, note payable to affiliated party     1,000       1,000  
    Total Current Liabilities     1,841,238       1,484,993  
Total Liabilities     1,841,238       1,484,993  
STOCKHOLDERS' EQUITY (DEFICIT)                
Preferred Stock ($.001 par value) 20,000,000 shares authorized; 1,963,821 issued and outstanding as of September 30, 2011 and September 30 2012     197       197  
Series AA Preferred ($.0001 par value) 100,000 shares authorized; 4,852 and 94,852 issued and outstanding as of September 30, 2011 and September 30, 2012     9          
Series B Preferred Shares ($0.0001) par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of September 30, 2011 and September  30 , 2012     73       73  
Common Stock ($0.0001 par value) 1,000,000,000 shares authorized; 72,189,747 and 323,507,887 issued and outstanding as of September 30, 2011 and  September 30 , 2012     32,350       7,219  
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 75,000 and 0 issued and outstanding as of September 30, 2012 and September 30, 2011     75,000          
Additional Paid in capital     12,490,780       11,498,731  
Contributed Capital     509,355       509,355  
Retained Earnings (Deficit) accumulated during the development stage     27,747,921       29,101,648  
Accumulated Other Comprehensive Income (Loss)     (41,314,361 )     0  
Equity in Earnings (Loss) of subsidiary     (663,649 )     (264,567 )
Deficit attributable to noncontrolling interest in subsidiary     (536,961 )     (536,961 )
Total Stockholders' Equity (Deficit)     (1,659,286 )     40,315,695  
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)   $ 181,952     $ 41,800,688  


The Accompanying Notes are an Integral Part of These Financial Statements




BIO MATRIX SCIENTIFIC GROUP,INC            
(A Development Stage Company)            
Consolidated Statement of Operations            
           
  12 months Ended   12 months Ended   From inception through
  September 30,   September 30,   September 30,
  2012   2011   2012
  REVENUES§   $ -     $ -     $ -  
COST AND EXPENSES                        
Research and Development     17,715       51,286       1,272,886  
General and Administrative     564,479       550,769       6,670,301  
Depreciation and Amortization                     2,668  
Consulting and Professional Fees     213,232       63,692       5,023,946  
Impairment of Goodwill and Intangibles                     34,688  
Total Costs and Expenses     795,426       665,747       13,004,489  
OPERATING LOSS     (795,426 )     (665,747 )     (13,004,489 )
OTHER INCOME & (EXPENSES)                        
Interest Expense     (55,139 )     (62,829 )     (413,674 )
Loss on Early Extinguishment of Debt     (41,688 )             (41,688 )
Interest Expense attributable to amortization of discount     (374,338 )             (374,338 )
Interest Income                     306  
Securities issued pursuant to contractual obligations     (66,372 )             (66,372 )
Other Income     25       146,791       176,916  
Gain on de-consolidation of subsidiary             42,182,649       42,182,649  

http://www.otcmarkets.com/stock/BMSN/filings  

Nix Elementares, nur diese Anmerkung ist von Bedeutung:

EXPLANATORY NOTE:

THIS AMENDMENT NO.1 TO BIO-MATRIX SCIENTIFIC GROUP, INC"S (THE "COMPANY") FORM 10-K FOR THE PERIOD ENDED SEPTEMBER 30, 2012 ("FORM 10-K") IS BEING FILED SOLELY TO CORRECT A TYPOGRAPHICAL ERROR. THE  CONSOLIDATED STATEMENT OF OPERATIONS FOR THE 12 MONTHS ENDED SEPTEMBER 30, 2011 REPORTED LOSS ON SALE OF AVAILABLE FOR SALE SECURITIES OF $487,900 AND THE  CONSOLIDATED STATEMENT OF OPERATIONS FOR THE PERIOD FROM INCEPTION TO SEPTEMBER 30, 2012 REPORTED LOSS ON SALE OF AVAILABLE FOR SALE SECURITIES OF $0. IN ACTUALITY LOSS ON SALE OF AVAILABLE FOR SALE SECURITIES WAS $0 AND $487,900 FOR THE 12 MONTHS ENDED SEPTEMBER 30, 2011 AND FROM INCEPTION TO SEPTEMBER 30, 2012 RESPECTIVELY

Es handelt sich um eine fälschliche Angabe im letzten 10K. Und zwar wurde in der Position "Loss on Sale of..." ein Verlust in 2011 anstatt in 2012 ausgewiesen. Dies wurde nun korrigiert...  

 

 

http://online.wsj.com/article/...0607-905535.html?mod=googlenews_wsj#  

..da haben wir drauf gewartet...heute ist der Wendepunkt...anschnallen

...aber wie kann man den gesamten Artikel aufrufen?

 

Bmsn  da kommt es doch fast immer als man denkt

ich ahne nichts Gutes  

BMSN neue Daten für die Wirksamkeit von HemaXellerate vorlegt, halte ich das für eine gute Nachricht...oder habe ich da etwas falsch verstanden???

 

Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today its submission of responses to the U.S. Food and Drug Administration's (FDA) comments regarding its IND # 15376 covering the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury.
"We are pleased with the responses that we have provided to the FDA and look forward to initiating our clinical trials," stated David Koos, Chairman and CEO of Regen BioPharma. "Although it is possible that a second round of comments may be issued, we feel this process is extremely useful to creating a clinical trial that is optimized for safety and detection of efficacy."
The HemaXellerate clinical trial aims to recruit 10 patients with aplastic anemia that have not shown material signs of improvement under the current the standard of care. If successful, the company will progress to larger efficacy-finding trials, as well as expansion to other diseases that would benefit from enhancement of bone marrow stem cells.
The scientific rationale for HemaXellerate, as well as some of the supporting data, may be found in the peer reviewed publication titled "Exogenous endothelial cells as accelerators of hematopoietic reconstitution," which is available at this link http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf
Currently there is a need for therapies that stimulate bone marrow stem cells. HemaXellerate utilizes cells derived from the patient's own fat stem cells to repair and stimulate the hematopoietic stem cells of the bone marrow, which are responsible for production of blood. The current market for therapies that stimulate blood cell production is in the billions of dollars per year. Neupogen and Neulasta, two products that stimulate production of white blood cells had sales of $4.84 Billion in 2010 http://www.wikinvest.com/stock/Amgen.
About Bio-Matrix Scientific Group, Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) through its wholly owned subsidiary, Regen BioPharma, Inc., is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
Disclaimer:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:

Bio-Matrix Scientific Group, Inc. and

Regen BioPharma Inc.

David R. Koos, PhD

Chairman & Chief Executive Officer

619-702-1404

www.regenbiopharma.com  

Dachte, der link würde funzen. Hoffe, ds ist mal was handfestes nun.
Dank an jotte fürs einstellen. Ich gene mir next time mehr Mühe...
Frk.  

Bin mal Fett eingestiegen heute noch zu 0,0024 Dollar :-)))  

..trotzdem trauriger verlauf, die will anscheinend ...nie mehr hoch  

News falsch verstanden das bmsn eine fda zulassung haben und sie an patienten testen dürfen?  

ja, so verstehe ich das auch.
Vorbehaltlich weiterer Fragen durch die fda.

Wie auch immer: ich denke, es wird ein sehr spannender Monat.....  

...steigen jetzt Investoren ein?  

 

...... Hoffentlich läuft es jetzt mal  

http://ih.advfn.com/...bol=BMSN&period=0&size=19&volume=1